Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label cirrhosis. Show all posts
Showing posts with label cirrhosis. Show all posts
Sunday, January 5, 2020

Study: Unhealthy Alcohol Use After HCV Therapy

›
HEPATOLOGY COMMUNICATIONS, VOL. 0, NO. 0, 2019  Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivir...
Tuesday, December 31, 2019

Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients

›
Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in no...
Saturday, March 2, 2019

Current and future pharmacological therapies for managing cirrhosis and its complications

›
World J Gastroenterol. Feb 28, 2019; 25(8): 888-908 Published online Feb 28, 2019. doi: 10.3748/wjg.v25.i8.888 Current and future pharm...
Saturday, February 23, 2019

Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessment

›
Cancer Med. 2019 Feb 21. doi: 10.1002/cam4.1998. [Epub ahead of print] Real impact of liver cirrhosis on the development of hepatocellular ...
Tuesday, February 19, 2019

Understanding Liver Disease with Dr. Joe Galati

›
Understanding Liver Disease with Dr. Joe Galati In this timeless patient-friendly video, Dr. Joe Galati will explain medical jargon used ...
Wednesday, February 13, 2019

Cirrhosis: What Clinicians Need to Know

›
Cirrhosis: What Clinicians Need to Know Listen to Christine Kerr, MD, AAHIVS, of Hudson River HealthCare, discuss specific challenges in...
Monday, February 11, 2019

Gilead Data On Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

›
Media A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial By Adam Feuerstein @adamfeuerstein Fe...
Monday, February 4, 2019

Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.

›
World J Hepatol. 2019 Jan 27;11(1):1-18. doi: 10.4254/wjh.v11.i1.1. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive r...
Thursday, January 17, 2019

After The Cure: What’s Next? Hepatitis C Post-Treatment Management

›
Listen to experts discuss important HCV related topics in the following easy to access webinar series provided by HepCure . Achieved SVR...
Tuesday, January 1, 2019

Editorial: Long-awaited treatment for hepatitis C virus decompensated cirrhosis

›
Journal of Gastroenterology pp 1–2 | Long-awaited treatment for hepatitis C virus decompensated cirrhosis Kiminori Kimura Editorial First...
Friday, November 30, 2018

Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment

›
Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simula...

Perinatal Exposure to HCV Leads to Earlier Cirrhosis

›
Recommended Reading Liver Meeting 2018  Sofosbuvir/ledipasvir cures most young children with hepatitis C Liz Highleyman / 13 November ...
Thursday, November 29, 2018

Ribavirin Beneficial For Patients with Hepatitis C Genotype 3

›
Ribavirin Beneficial For Patients with Hepatitis C Genotype 3 NOVEMBER 29, 2018 Kenneth Bender, PharmD, MA The addition of ribavirin t...
Thursday, November 22, 2018

Blogging About Liver Disease: Reasons To Be Grateful

›
Happy Thanksgiving! This year, and every year, I am grateful for a small group of talented bloggers who continue to keep us informed abo...
Tuesday, November 13, 2018

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

›
The Liver Meeting® 2018 Meeting Updates  View all updates on this blog, ( LINK ), coverage elsewhere, (LINK ). Related Links: High S...
Monday, November 12, 2018

High SVR12 rate for 16 week glecaprevir/pibrentasvir regimen in HCV GT1

›
Combo HCV Pill Effective in Certain Refractory Patients High SVR12 rate for 16 week glecaprevir/pibrentasvir regimen in HCV GT1 patients ...

AASLD Poster Roundup: Factors that Impact Cirrhosis Diagnosis

›
Meeting Coverage > AASLD AASLD Poster Roundup: Factors that Impact Cirrhosis Diagnosis Selections from poster sessions at the annua...
Sunday, November 11, 2018

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

›
In Case You Missed It Can J Gastroenterol Hepatol. 2018 Oct 3;2018:6095097. doi: 10.1155/2018/6095097. eCollection 2018. Glucose Met...
Monday, October 29, 2018

Mavyret (glecaprevir/pibrentasvir) 8 Wks Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function

›
Infect Dis Ther. 2018 Oct 27. doi: 10.1007/s40121-018-0218-x. [Epub ahead of print] Pan-Genotypic Hepatitis C Treatment with Glecaprevir a...
Sunday, October 28, 2018

Long term outcome of antiviral therapy in HBV patients with cirrhosis

›
World J Gastroenterol. Oct 28, 2018; 24(40): 4606-4614 Published online Oct 28, 2018. doi: 10.3748/wjg.v24.i40.4606 Long term outcome of ...